Dishman Carbogen Amcis (DCAL)₹167.10+3.03%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Dishman Carbogen Amcis reported sales of ₹677 Cr, down 4.3% from Jun 2025, and net profit of −₹57.75 Cr, down 352.0% year on year. For the year to Mar 2026, sales were ₹2,927 Cr and net profit ₹96.62 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 585 | 650 | 654 | 522 | 787 | 680 | 714 | 707 | 651 | 719 | 849 | 677 |
| Expenses | 525 | 610 | 591 | 495 | 642 | 542 | 563 | 567 | 503 | 606 | 687 | 618 |
| Operating Profit | 61.03 | 40.99 | 63.02 | 28.99 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 59.98 |
| OPM % | 9.9% | 6.0% | 10.0% | 6.0% | 19.0% | 21.0% | 21.0% | 20.0% | 23.0% | 15.9% | 19.0% | 9.0% |
| Other Income | 4.99 | 5.98 | 3.99 | −3.99 | 3.99 | 7.98 | −3.99 | 21.93 | 7.97 | 6.98 | 14.95 | 15.96 |
| Interest | 26.94 | 32.91 | 30.92 | 31.94 | 36.90 | 48.87 | 41.90 | 42.93 | 41.94 | 45.93 | 42.93 | 36.93 |
| Depreciation | 74.82 | 79.84 | 84.79 | 70.84 | 71.92 | 71.82 | 78.93 | 80.85 | 83.84 | 83.91 | 88.81 | 90.79 |
| Profit before tax | −35.98 | −66.02 | −49.01 | −77.96 | 41.99 | 27.01 | 27.99 | 39.02 | 30.99 | −10.01 | 45.99 | −50.98 |
| Tax % | 12.9% | −10.1% | 41.9% | 0.0% | 20.9% | 82.9% | −56.1% | 38.9% | −114.1% | 23.9% | 52.9% | 12.9% |
| Exceptional items | −2.01 | 0.00 | −1.01 | −5.01 | −1.01 | 0.00 | −12.02 | −1.01 | 0.00 | 0.00 | −1.01 | −1.01 |
| Net Profit | −40.85 | −59.76 | −69.70 | −77.71 | 32.90 | 4.98 | 42.86 | 22.92 | 64.76 | −12.95 | 21.91 | −57.75 |
| EPS (Rs) | −2.62 | −3.81 | −4.47 | −4.96 | 2.12 | 0.31 | 2.76 | 1.50 | 4.17 | −0.84 | 1.40 | −3.70 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,709 | 1,690 | 2,054 | 2,038 | 1,908 | 2,134 | 2,405 | 2,610 | 2,704 | 2,927 | 2,896 |
| Expenses | 1,260 | 1,247 | 1,505 | 1,539 | 1,635 | 1,808 | 2,079 | 2,327 | 2,240 | 2,362 | 2,414 |
| Operating Profit | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 566 | 485 |
| OPM % | 25.9% | 26.0% | 27.0% | 25.0% | 14.0% | 15.0% | 14.0% | 11.0% | 17.0% | 19.0% | 16.8% |
| Other Income | 25.91 | 45.87 | 53.85 | 38.90 | 15.94 | 28.91 | −19.94 | 21.93 | 3.99 | 51.84 | 45.86 |
| Interest | 48.87 | 48.87 | 56.83 | 61.90 | 47.91 | 56.90 | 85.86 | 120 | 159 | 174 | 168 |
| Depreciation | 214 | 211 | 239 | 282 | 307 | 307 | 280 | 310 | 294 | 338 | 347 |
| Profit before tax | 216 | 231 | 309 | 197 | −64.99 | −3.99 | −54.98 | −122 | 18.99 | 105 | 15.99 |
| Tax % | 32.9% | 32.9% | 31.9% | 19.9% | 153.9% | −524.1% | −45.1% | 25.9% | 82.9% | 7.0% | — |
| Exceptional items | 2.01 | 1.01 | 3.01 | −5.01 | 5.01 | −32.04 | −21.01 | −2.01 | 22.03 | −2.01 | −2.02 |
| Net Profit | 145 | 154 | 209 | 159 | −165 | 17.94 | −29.90 | −152 | 2.99 | 96.62 | 15.97 |
| EPS (Rs) | — | 9.61 | 13.06 | 10.11 | −10.55 | 1.16 | −1.91 | −9.81 | 0.22 | 6.24 | 1.03 |
| Dividend payout % | 0.0% | 0.0% | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.00 | 32.12 | 32.13 | 31.12 | 31.13 | 31.13 | 31.11 | 31.10 | 31.14 | 31.12 |
| Reserves | 4,809 | 5,069 | 5,341 | 5,677 | 5,658 | 5,516 | 5,775 | 5,589 | 5,796 | 6,637 |
| Borrowings | 951 | 1,096 | 1,043 | 1,359 | 1,591 | 1,831 | 2,211 | 2,315 | 2,389 | 3,080 |
| Other Liabilities | 809 | 970 | 897 | 1,126 | 1,072 | 1,254 | 1,414 | 1,631 | 1,761 | 2,164 |
| Total Liabilities | 6,569 | 7,166 | 7,315 | 8,193 | 8,353 | 8,632 | 9,431 | 9,566 | 9,978 | 11,913 |
| Fixed Assets | 4,843 | 5,057 | 5,086 | 5,671 | 5,688 | 5,765 | 6,171 | 6,711 | 7,039 | 8,353 |
| CWIP | 133 | 151 | 175 | 234 | 487 | 782 | 1,045 | 647 | 468 | 275 |
| Investments | 39.93 | 195 | 167 | 191 | 172 | 323 | 249 | 102 | 96.82 | 90.81 |
| Other Assets | 1,554 | 1,763 | 1,886 | 2,098 | 2,007 | 1,762 | 1,966 | 2,106 | 2,375 | 3,194 |
| Inventories | 427 | 486 | 550 | 582 | 517 | 646 | 805 | 884 | 902 | 1,021 |
| Trade receivables | 286 | 443 | 445 | 577 | 421 | 473 | 590 | 483 | 665 | 673 |
| Cash & equivalents | 87.32 | 69.18 | 96.26 | 162 | 309 | 173 | 190 | 414 | 509 | 994 |
| Total Assets | 6,569 | 7,166 | 7,315 | 8,193 | 8,353 | 8,632 | 9,431 | 9,566 | 9,978 | 11,913 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 302 | 225 | 281 | 584 | 512 | 354 | 266 | 378 | 374 | 490 |
| Cash from investing activity | −107 | −296 | −169 | −441 | −379 | −617 | −493 | −224 | −195 | −244 |
| Cash from financing activity | −137 | 77.81 | −102 | −97.70 | −10.97 | 130 | 249 | −21.95 | −102 | 201 |
| Net cash flow | 59.16 | 7.02 | 11.03 | 46.13 | 122 | −134 | 22.08 | 132 | 77.31 | 448 |
| Capex | 148 | 216 | 308 | 410 | 367 | 465 | 621 | 304 | 217 | 267 |
| Free cash flow | 164 | 21.98 | −26.01 | 177 | 147 | −101 | −352 | 76.03 | 160 | 225 |
| CFO / OP % | 92.0% | 58.0% | 75.1% | 131.0% | 206.1% | 124.1% | 90.0% | 139.0% | 86.0% | 88.0% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 61 | 96 | 79 | 103 | 80 | 81 | 89 | 68 | 90 | 84 |
| Inventory days | 473 | 525 | 496 | 462 | 402 | 526 | 568 | 540 | 655 | 910 |
| Days payable | 96 | 202 | 177 | 227 | 133 | 159 | 156 | 150 | 169 | 190 |
| Cash conversion cycle | 439 | 419 | 399 | 340 | 350 | 449 | 502 | 458 | 577 | 805 |
| Working capital days | 35 | 44 | 43 | −10 | −2 | −8 | −37 | −148 | −35 | −58 |
| ROCE % | — | 5.0% | 6.0% | 4.0% | 0.0% | 1.0% | 1.0% | 0.0% | 2.0% | 3.0% |
For the Jun 2026 quarter, Dishman Carbogen Amcis reported sales of ₹677 Cr, down 4.3% year on year and net profit of −₹57.75 Cr, down 352.0% year on year. The operating margin was 9.0%.
Dishman Carbogen Amcis' sales for the year to Mar 2026 were ₹2,927 Cr; over the last twelve months they were ₹2,896 Cr.
Net profit for the year to Mar 2026 was ₹96.62 Cr, and ₹15.97 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.03.
Dishman Carbogen Amcis reported borrowings of ₹3,080 Cr at Mar 2026, against cash and equivalents of ₹994 Cr.
Cash from operations was ₹490 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹225 Cr.